India's Comprehensive Economic Partnership Agreement with Oman comes into effect on June 1, granting New Delhi 100% duty-free access for 98...

A corporate crisis manager describes how business disputes in India are increasingly being turned into criminal cases, exposing executives ...

Officials at both the finance ministry and Niti Aayog are identifying economic opportunities presented by the Iran conflict, as well as gau...

India has eased Foreign Direct Investment rules for companies with up to ten percent Chinese or Hong Kong shareholding. These firms can now...

India and New Zealand signed a “once-in-a-generation” free trade agreement on Monday that gives New Delhi duty-free access to 100% of tarif...

Saurabh Mukherjea believes India's long-standing economic model is concluding. He anticipates rising inflation and a weakening rupee impact...

"The pharma industry is growing by 14 per cent every year. With relaxed FDI norms, I think pharma sector will grow by 20 per cent," Kumar s...

According to a proposal, FDI up to 49% should be allowed through the automatic route and anything beyond through approval of the FIPB, sour...

The committee demands caution on the issue from the government and reiterates its recommendation to impose a blanket ban in FDI in brown fi...

FDI in drugs and pharmaceuticals was at $580 million during April-October 2012, according to the data of the Department of Industrial Polic...

Currently, 100 per cent FDI is permitted in brownfield pharma firms through clearance from the Foreign Investment Promotion Board (FIPB).

The decision on FDI in pharma and housing has been deferred, Information and Broadcasting Minister Manish Tewari said after the Cabinet mee...

The Ministry of Commerce and Industry has proposed tighter overseas investment norms in existing drug companies by limiting all forms of fo...

Faced with rush of multinationals to acquire Indian pharma firms, the Commerce and Industry Ministry is proposing to tighten the FDI policy...

Commerce Minister Anand Sharma has urged Prime Minister Manmohan Singh to convene a high-level review meeting to deliberate on the matter.

The DIPP said current norms must lay down the foundation of what should be the nature of Indian drug companies in the long term.

The government is likely to finalise FDI policy with regard to existing drug companies ahead of the FIPB meeting on July 5.